

HR 5894

Transparency in Prescription Drug Advertising Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 13, 2020

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Feb 13, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/5894>

Sponsor

Name: Rep. Davids, Sharice [D-KS-3]

Party: Democratic • **State:** KS • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Finkenauer, Abby [D-IA-1]	D · IA		Feb 13, 2020
Rep. Slotkin, Elissa [D-MI-8]	D · MI		Feb 13, 2020
Rep. Perlmutter, Ed [D-CO-7]	D · CO		May 1, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 13, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Transparency in Prescription Drug Advertising Act

This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency.

On May 10, 2019, the CMS issued a final rule titled *Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency*. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least \$35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.

Actions Timeline

- **Feb 13, 2020:** Introduced in House
- **Feb 13, 2020:** Referred to the House Committee on Energy and Commerce.